帕拉米韦联合头孢噻肟治疗流感病毒肺炎患者的效果观察  

Observation of the Efficacy of Peramivir Combined with Cefotaxime in the Treatment of Influenza Virus Pneumonia Patients

作　　者：辛全娟 姜伟 XIN Quanjuan;JIANG Wei(Department of Respiratory and Critical Care Medicine,Rizhao Central Hospital,Rizhao 276800,China;Department of General Practice,Donggang District Shijiu Street Community Health Service Centers of Rizhao,Rizhao 276800,China)

机构地区：[1]日照市中心医院呼吸与危重症医学科,山东日照276800 [2]日照市东港区石臼街道社区卫生服务中心全科医学科,山东日照276800

出　　处：《反射疗法与康复医学》2024年第14期123-125,共3页Reflexology And Rehabilitation Medicine

摘　　要：目的探讨帕拉米韦联合头孢噻肟治疗流感病毒肺炎患者的临床效果。方法选择2020年6月—2023年6月日照市中心医院收治的78例流感病毒肺炎患者为研究对象,按随机数字表法将其分为对照组和观察组,各39例。对照组予以患者头孢噻肟治疗,观察组在对照组基础上联合帕拉米韦治疗,两组均连续治疗3 d。比较两组的临床疗效、临床症状消失时间、炎症反应、不良反应发生情况。结果观察组治疗总有效率为94.87%,高于对照组的79.49%,差异有统计学意义(P<0.05)。观察组咳嗽、发热、咽痛及流涕消失时间均短于对照组,组间差异有统计学意义(P<0.05)。治疗后,观察组C反应蛋白、肿瘤坏死因子-α、细胞间黏附分子-1、白细胞介素-6水平均低于对照组,组间差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论帕拉米韦联合头孢噻肟治疗流感病毒肺炎患者可有效减轻其临床症状和炎症反应,且安全性高。Objective Exploring the clinical efficacy of peramivir combined with cefotaxime in the treatment of influenza virus pneumonia patients.Methods A total of 78 patients with influenza virus pneumonia admitted to Rizhao Central Hospital from June 2020 to June 2023 were selected as the research subjects,according to the random number table method,they were divided into a control group and an observation group,with 39 cases in each group.The control group was treated with cefotaxime,while the observation group was treated with combination therapy with peramivir on the basis of the control group,both groups were treated continuously for 3 days.Compare the clinical efficacy,disappearance time of clinical symptoms,inflammatory response,and occurrence of adverse reactions between two groups.Results The total effective rate of the observation group was 94.87%,which was higher than 79.49% of the control group,the difference was statistically significant(P<0.05).The disappearance time of cough,fever,sore throat,and runny nose in the observation group were shorter than those in the control group,the differences between the groups were statistically significant(P<0.05).After treatment,the levels of C-reactive protein,tumor necrosis factor-α,intercellular adhesion molecule-1,and interleukin-6 in the observation group were lower than those in the control group,the differences between the groups were statistically significant(P<0.05).Comparison of incidence of adverse reactions between two groups,the difference was not statistically significant(P>0.05).Conclusion Peramivir combined with cefotaxime can effectively alleviate clinical symptoms and inflammatory reactions in patients with influenza virus pneumonia,and has high safety.

关 键 词：流感病毒肺炎 帕拉米韦 头孢噻肟 炎症反应 

分 类 号：R563.1[医药卫生—呼吸系统]